The “entourage effect” is the idea that the many compounds in cannabis work better together than THC or CBD alone. Sellers use it to market full-spectrum oils, strains and terpene blends. This part explains how a narrow 1998 laboratory finding became a sales slogan. It then compares isolate, broad-spectrum and full-spectrum products and sets out the Thai rules. It sorts the 2026 evidence into what is supported and what is not, and it ends with what you can say and do as a grower or seller in Thailand.
This article brings together many published studies rather than translating a single source. Every study it relies on is listed under References at the end.
Some background is needed first. THC (tetrahydrocannabinol) causes the cannabis high, and CBD (cannabidiol) does not. Terpenes are the compounds behind each cultivar’s smell. The term “entourage effect” first described molecules the human body makes itself (Ben-Shabat, Mechoulam and colleagues, 1998). Mechoulam was the Israeli chemist best known for working out the structure of THC. Ethan Russo, a US neurologist, applied the idea to plant compounds in a 2011 hypothesis paper. Only three human studies test the idea directly:
- a 2010 cancer-pain trial that favoured THC with CBD over a THC extract;
- a small 2024 trial in which the terpene limonene reduced THC-induced anxiety;
- a 2023 trial in which added CBD did not soften THC’s effects.
This is Part 2. Part 1: The Entourage Effect, Evidence vs. Marketing: Where the Idea Came From and What Laboratory and Human Studies Found (Part 1 of 2)
How the Term Became Marketing
The claim grew in five steps:
- A real finding in a narrow setting. The body’s own molecules showed an entourage effect (1998).
- An extension as a hypothesis into an area with commercial appeal: plant cannabinoids plus terpenes (Russo 2011).
- The hypothesis cited as evidence. People quote it and leave out the word “hypothesis”.
- “Full-spectrum is better than isolate” becomes a sales rule.
- Particular terpene profiles marketed as causing particular effects. For example, sellers describe a high-myrcene cultivar as “deeply relaxing”, as if there were data on myrcene’s effects in humans.
At each step the claim became more confident, but the evidence did not change.
Translator’s note: When you describe a strain or product, stay at steps 1 and 2. Give the measured cannabinoid and terpene content, describe the aroma and say how the crop grew. Do not promise an effect. This keeps your description true to the evidence. In Thailand it matters for a second reason: advertising cannabis flower is prohibited. The advertising rules topic explains what you may post.
Full-Spectrum, Broad-Spectrum, Isolate
| Product type | What it contains | Strength | Weakness |
|---|---|---|---|
| Isolate | One purified compound (pure CBD or pure THC) | Predictable dose and effect; easy to test in trials | Lacks the plant’s other compounds |
| Broad-spectrum | Other cannabinoids and terpenes, with the THC removed | No THC | Loses any THC–CBD combined effect |
| Full-spectrum | The cannabinoid and terpene profile of the source plant | Closest to Russo’s hypothesis | Hardest to standardise; varies from batch to batch |
Isolates have the most predictable effects. The response to each dose is easy to predict, and trials are easy to design. For specific epilepsy syndromes, pharmaceutical CBD isolate is the option with trial evidence. Prescribing it is a decision for a specialist doctor.
Broad-spectrum products have their THC removed, usually by one of two methods. Distillation separates compounds by their boiling points. Chromatography separates compounds by how fast they pass through a filtering material. The 2010 cancer-pain trial (Johnson and colleagues) hints that the most important interaction may be between THC and CBD. If so, removing THC also removes that part of any combined effect.
Full-spectrum products keep the plant’s cannabinoid and terpene profile. They fit Russo’s hypothesis best but are the hardest to standardise. The amounts of minor cannabinoids and terpenes vary from batch to batch, which makes dosing harder. Local law decides what a full-spectrum product may legally contain. The Thai rules are in the next section.
For adults who use these products where it is legal, and who have no specific medical diagnosis, the difference between two well-made products is unlikely to be noticeable. This applies to full-spectrum versus broad-spectrum. No human trial has compared the two. Product quality, accurate labelling and good storage probably matter more.
Translator’s note: Terpenes evaporate easily, and heat, light and air break them down. In rooms at 30–35 °C, or in a humid rainy season, a product can lose much of its aroma before anyone uses it. Store extracts and dried flower sealed, dark and cool. Check the test date on the certificate of analysis (COA). The terpene figures on an old certificate may no longer describe the product in your hand. The storage topic gives the details.
Thailand: What the Rules Say
- CBD and hemp-extract products are regulated by the Thai Food and Drug Administration (Thai FDA). Labels and advertising must follow Thai FDA rules. Do not present the “entourage effect” as a health benefit on a label or in an advert. The labelling topic covers Thai FDA label requirements.
- Extract licensing became stricter in 2026 under the Ministerial Regulation on Cannabis or Hemp Extracts B.E. 2569. It came into force on 26 April 2026. The topic on the two 2026 regulations explains the changes.
- Cannabis flower is a controlled herb. This status comes from the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis) B.E. 2568, which came into force on 26 June 2025.
- Flower may be sold only against a PT 33 (ภ.ท.33) prescription from an authorised practitioner.
- Each prescription covers no more than 30 days.
- The flower must come from a source certified for good cultivation and harvesting practice by the Department of Thai Traditional and Alternative Medicine.
- Flower may not be advertised in any channel or sold online.
- The notification limits flower to medical use.
- The Cannabis Control Act is still a draft, not law. The Cabinet approved the draft on 22 September 2026 and sent it to the House. The draft Act topic has the details.
- Epidiolex, the purified-CBD medicine described in Part 1, has not been confirmed as registered in Thailand. In September 2026 the Thai FDA announced that it had registered LEPSIA. LEPSIA is a pure-CBD anti-seizure medicine for children, developed by Chiang Mai University with a private-sector partner. Any use for epilepsy is a decision for a specialist doctor.
Translator’s note: Three more verified points matter to growers and makers.
-
Under the 2026 extract regulation, only certain bodies can be licensed for extracts with more than 0.2% THC:
- Thai juristic persons that are not “foreign” under the Foreign Business Act B.E. 2542;
- state agencies;
- the Thai Red Cross Society.
A full-spectrum extract above that THC level is therefore outside the reach of most small producers.
-
The Ministerial Regulation on Controlled Herbs (No. 2) B.E. 2569 came into force on 30 April 2026. It tightens the criteria for cannabis flower licences.
-
Selling or processing a controlled herb without a licence (Section 46 of the Thai Traditional Medicine Protection Act B.E. 2542) carries a penalty under Section 78. The penalty is up to one year in prison, a fine of up to 20,000 baht, or both.
Before you make or sell any extract, check which licence covers your activity. The licensing topic explains which licence covers what.
What the Evidence Supports in 2026
Supported
- The entourage effect among the body’s own molecules (Ben-Shabat, Mechoulam and colleagues 1998), in its original setting.
- Nabiximols (Sativex), a THC:CBD mouth spray, works for muscle spasticity in multiple sclerosis. In one cancer-pain trial it beat placebo, while a THC extract did not (Johnson 2010).
- β-caryophyllene binds to the CB2 receptor (Gertsch 2008). CB2 is one of the two main docking points for cannabinoids on cells.
- Some animal studies show whole-plant extracts behaving differently from single compounds (for example Gallily 2015).
Early human data, not yet repeated
- A terpene changing THC’s effects in people: in one small controlled trial, limonene reduced THC-induced anxiety (Spindle 2024).
Possible, but probably minor
- CBD slowing the liver’s breakdown of THC, which would raise THC levels in the blood. At nabiximols doses, this is probably of little practical importance.
Tested in one well-controlled trial and not found
- CBD softening THC’s effects. This did not happen at CBD:THC ratios from 1:1 to 3:1 with 10 mg THC (Englund 2023).
Proposed, but not tested in any study covered here
- Minor cannabinoids in full-spectrum products meaningfully changing outcomes. Examples are CBG (cannabigerol), THCV (tetrahydrocannabivarin) and CBC (cannabichromene). None of the studies covered in this article tested them.
Disputed
- Terpenes acting at the CB1 and CB2 receptors. Two cell studies were negative (Santiago 2019; Finlay 2020). One study in mice and cells was positive (LaVigne 2021).
Not supported
- Particular terpene profiles reliably predicting particular effects.
- Full-spectrum products being medically better than isolates for every use.
What to do: before you put any of these claims in a post, a strain description or a label, check which group above it falls into.
What You Can Do as a Grower or Seller in Thailand
Translator’s note: This section turns the evidence into concrete steps for growers in Thailand and Southeast Asia.
- Describe your strains by measured content and aroma, not by promised effects.
- Purpose: your description stays within the evidence and within Thai advertising rules.
- Start: rewrite one existing strain description this week. Remove words such as “relaxing” or “energising” that come only from the terpene profile.
- Get a cannabinoid and terpene test for one batch.
- Purpose: you learn your crop’s real profile instead of relying on the breeder’s claim.
- Start: ask your testing laboratory whether it offers a terpene panel alongside the cannabinoid test. The topic on testing and Thai laboratories explains what a certificate should show.
- Protect terpenes while drying and curing.
- Purpose: the certificate only shows what survives the process, and Thai heat and humidity cause losses.
- Start: log the temperature and humidity of your drying room twice a day during your next harvest. Compare the log with the aroma and the test result. The drying topic and the curing topic give target conditions.
- Write useful strain reviews.
- Purpose: other growers get data they can act on.
- Start: report how the plant grew, its aroma and any test figures, not “effects”. The strain review guide shows the format.
- Send patients to their prescriber.
- Purpose: the choice of product type is a medical decision.
- Start: a patient should ask their PT 33 prescriber about isolate versus full-spectrum and bring a list of all their current medicines. The drug interaction topic has a list to take along.
Conclusion
The entourage effect is a real scientific idea. It started with the body’s own molecules and was extended to plant compounds as a hypothesis. Only three human studies test it directly:
- one three-group cancer-pain trial that favours THC:CBD over a THC extract;
- one small terpene trial;
- one well-controlled trial in which CBD did not soften THC’s effects.
Three studies are not enough to back the confident claims made in shops and on labels.
The plant probably does contain more relevant chemistry than THC and CBD alone. How large that effect is, and whether it matters for patients, has not been shown. No evidence supports predicting effects from a terpene profile. Patients should discuss product type with a doctor who understands how cannabis compounds act in the body. Large head-to-head trials of isolate, THC plus CBD and full-spectrum extract would answer most of the open questions.
Until those trials exist, describe your products by what a laboratory measured, not by the effects a terpene is said to cause. If you have test results or grow notes that bear on this topic, post them below so others can compare.
Further reading on Asiannabis
- Terpenes in Cannabis: What They Are, How Much Survives Drying, and Which Effect Claims the Evidence Supports
- The Cannabinoid Family: What Is Actually Known About Tetrahydrocannabinol, Cannabidiol, Cannabigerol, Cannabinol and the Rest
References
- Ben-Shabat S, Mechoulam R, et al. (1998). European Journal of Pharmacology. The paper that introduced the endocannabinoid entourage effect.
- McPartland JM, Russo EB (2001). “Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?” Journal of Cannabis Therapeutics.
- Russo EB (2011). “Taming THC: Potential Cannabis Synergy and Phytocannabinoid–Terpenoid Entourage Effects.” British Journal of Pharmacology.
- Santiago M, et al. (2019). “Absence of Entourage.” Cannabis and Cannabinoid Research.
- Finlay DB, et al. (2020). “Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors.” Frontiers in Pharmacology 11:359.
- LaVigne JE, et al. (2021). “Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity.” Scientific Reports.
- Gertsch J, et al. (2008). PNAS. β-caryophyllene binding to CB2.
- Gallily R, et al. (2015). Pharmacology & Pharmacy. CBD-rich extract versus purified CBD in mice.
- Johnson JR, et al. (2010). Journal of Pain and Symptom Management. THC:CBD extract versus THC extract versus placebo in cancer pain.
- Englund A, et al. (2023). Neuropsychopharmacology. CBD at 0–30 mg with 10 mg vaporised THC.
- Spindle TR, et al. (2024). Drug and Alcohol Dependence. Vaporised THC with and without d-limonene.